Signal detail

News insight

Source-backed analysis, the reasoning behind the signal, and its market context.

FMCBearishEarningsShort Term

High materiality8/10

FMC Corporation reports second quarter 2026 results with Adjusted EBITDA above high end of guidance range and solid cash generation

StockNews.AIJul 29, 4:30 PM EDT1 source

Trading thesisImportance 8/10

Near-term downside risk on softer 2026 guidance; potential upside if India sale closes and debt paydown accelerates within 12–18 months.

AI summary

What happened and why it matters

FMC reported Q2 2026 revenue of $867M, with ex-India revenue of $841M, both down meaningfully year over year. The company posted a GAAP loss of $1.49 per diluted share and adjusted EBITDA of $153M, while free cash flow reached $357M, aided by a $200M upfront licensing payment for rimisoxafen. FMC outlined a plan to generate roughly $1B of debt-reduction proceeds from asset sales, including its India business sale, Newark property, and a Tessenderlo investment, as it refreshes guidance and strategy for 2026.

India held-for-sale divestiture advances with a $252M sale agreement; closing expected in 2026.
Approximately $1B of debt-reduction proceeds targeted from asset sales (India, Newark, Tessenderlo).
Upfront rimisoxafen licensing payment of $200M boosted current cash flow; non-GAAP effects highlighted.
Full-year 2026 outlook updated: ex-India revenue $3.50–$3.70B; EBITDA $620–$680M; EPS $1.19–$1.49.

Sentiment rationale

Softening top-line and earnings amid macro headwinds, despite strong cash flow, suggest near-term multiple compression; optionality from asset sales and India exit provides longer-term upside, but timing is uncertain.

Key facts

01
Q2 2026 revenue $867M, down 17% YoY.
02
Ex-India revenue $841M, down 20% YoY; organic down 22%.
03
GAAP net loss $187M; Adjusted EBITDA $153M, down 26%.
04
FCF $357M; OCF $363M aided by $200M rimisoxafen upfront payment.
05
Outlook: 2026 revenue $3.50–$3.70B; EBITDA $620–$680M; EPS $1.19–$1.49.

Earnings

Category: Earnings. The release centers on quarterly results and full-year guidance, with strategic moves (India sale, debt reduction) shaping FMC's risk/reward profile and capital structure going forward.